8th Annual Jefferson Liver Disease Symposium - Virtual Meeting

April 9, 2022

The 8th Annual Jefferson Liver Disease Symposium 2022 is a one day, virtual program that focuses on relevant information regarding new developments in Hepatology, and new approaches to the management of liver diseases that can be readily integrated into daily practice of gastroenterologists, primary care physicians, nurses, and other members of the healthcare team. Experts in the fields of Hepatology, gastroenterology, and surgery will share their expertise and new findings on a broad range of topics including hepatitis disorders, miscellaneous liver disorders, and liver transplant-related topics.

Keynote Speaker

 

Dr. David Kaplan is board-certified in Internal Medicine, Gastroenterology and Transplant Hepatology. His clinical expertise is in cirrhosis, viral hepatitis, hepatocellular carcinoma and fatty liver. His research interests include translational research in therapy for liver cancer, epidemiological research into the relationship of medication exposures and the natural history of chronic liver disease, and clinical research related to cirrhosis. 

 

Successful Completion

To successfully complete this activity, the required evaluation must completed by the stated date. Thereafter, the evaluation will no longer be available and credits will not be issued. No refunds will be offered for failure to complete the required evaluation by the stated deadline.

  • Pharmacists must complete the required evaluation no later than Monday, May 9, 2022. This is to allow time for upload into CPD Monitor.
  • All other attendees must complete the required evaluation must be completed no later Tuesday, May 24, 2022.

Target Audience

This course is designed for gastrointestinal specialists, primary care physicians, internists, surgeons and nurse practitioners, and nurses who treat or manage patients with liver disorders.

Learning Objectives

Following this educational symposium, learners will be able to:

Topic Area 1: Hepatitis and Genetic Disorders

  1. Interpret metabolic factors associated with NASH to identify individuals at risk of developing progressive fibrosis.
  2. Discuss potential pharmacologic agents that have pathophysiologic disease targets in NASH.
  3. Compare the history of HBV treatments to current treatment options.
  4. Employ current guidelines for testing, diagnosing, and treating patients with chronic hepatitis B.
  5. Judge the diagnostic scoring system and histologic features of AIH, based on the most recently published AASLD Practice Guidelines.
  6. Describe the second-line therapies that can be used for corticosteroid/azathioprine failures.
  7. Describe the pathophysiology, clinical manifestations, diagnosis and treatment of the most common porphyrias.
  8. Evaluate novel treatment options for acute hepatic porphyrias.

Topic Area 2: Cirrhosis and Liver Cancer

  1. Use the current pharmacologic and loco-regional treatments for HCC.
  2. Value a multi-disciplinary team approach to HCC management.
  3. Explain the diagnostic criteria for ACLF.
  4. Describe the available supportive therapies for ACLF and the role of liver transplantation.
  5. Define what is meant by “frailty” and “sarcopenia” in liver disease. 
  6. Adapt the 2021 Practice Guidance from the AASLD for malnutrition, frailty and sarcopenia.
  7. Describe factors used to risk stratify patients with cirrhosis prior to surgery.
  8. Contrast different surgical risk scores in prognosticating surgical outcomes.

Topic Area 3: Advancements in Liver Transplantation

  1. Describe the strategy of HCV (+) to HCV (-) solid organ transplantation.
  2. Construct post-op treatment strategies for early diagnosis and management of donor derived HCV (+) infections.
  3. Recognize the role of LDLT in the field of liver transplantation.
  4. Describe the diagnostic testing that the donors are subjected to in assessing their candidacy for donation.
  5. Summarize the Jefferson Living Donor Liver Transplant experience.
  6. Explain the benefits of the Ex-vivo OCS for preserving a liver allograft over the currently employed ischemic cold storage system.
  7. Describe how new liver preservation techniques can significantly impact liver transplant volumes and post-operative outcomes.
     
Additional information
Jefferson Content Development By: 
Sidney Kimmel Medical College (SKMC)
Thomas Jefferson University Hospital (TJUH)
Content Areas: 
Family Medicine
Gastroenterology
Hepatology
Internal Medicine
Surgery
Transplantation
Course Format: 
Live Webinar
Course summary
Available credit: 
  • 6.67 ACPE
  • 6.75 AMA PRA Category 1 Credit
  • 6.75 Attendance
  • 6.67 CNE
  • 2.00 CNE Pharmacotherapy
  • 3.25 Patient Safety
Course opens: 
01/05/2022
Course expires: 
05/24/2022
Event starts: 
04/09/2022 - 8:00am EDT
Event ends: 
04/09/2022 - 3:05pm EDT
Cost:
$125.00

Commercial/IN-KIND SUPPORT

Any sponsorship received for this educational activity will be published and announced prior to the start of the activity.

Agenda

Agenda subject to change.


 

This activity is a live virtual meeting.
Zoom login information will be provided to registrants prior to the start of the activity.
United States

Required Hardware/Software

This activity will be using Zoom teleconferencing software. Click here to view the system requirements.

Course Director

Dr. David Sass is a Jefferson University physician and the Medical Director for the Liver Transplant Program at Jefferson. He specializes in Gastroenterology and Hepatology.

 


Disclosures

Thomas Jefferson University Office of Continuing Professional Development (OCPD) endorses the ACCME Standards for Commercial Support: Standards to Ensure Independence in CME Activities and the policies that supplement the Standards. All planners, faculty, authors, presenters, and content reviewers are required to disclose any financial relationships with ACCME defined ineligible entities within the past 24 months. Any conflict of interests have been mitigated prior to the educational activity.

Such disclosures will be available prior to the start of the activity. ​OCPD Conflict of Interest resolution process may result in changes to the program agenda.

Planning Committee

No member of the planning committee have any financial relationships to disclose.
David A. Sass, MD, FACP, FACG, AGAF, FAASLD-Course Director
Ann Burke, CRNP
Sarah Yeager, PharmD

Faculty

The following faculty members of no financial relationships to disclose.
David A. Sass, MD, FACP, FACG, AGAF, FAASLD
Jesse M. Civan, MD
Steven K. Herrine, MD, FAASLD
Danielle M. Tholey, MD
Ashesh P. Shah, MD

The following faculty members have financial relationships to disclose.
Dina L. Halegoua De-Marzio, MD
  Researcher: Aramchol, BMS, Genfit, Gilead, Intercept; Consultant: Gilead, Intercept
Scott A. Fink, MD MPH
  Speaker: Abbvie, Galead; Consultant: Gilead, Mallinkckdrodt Pharmaceuticals; Advisor: Gilead, Mallinckdrodt Pharmaceuticals
Manish Thapar, MD FAASLD
  Consultant/Speaker: Alnylam
Jonathan M. Fenkel, MD
  Researcher: Abbvie, Gilead, Alexion; Consultant: Alexion, Gilead
Hie-Won Hann, MD, FAASLD
  Advisory Board/Researcher: Gilead
David E. Kaplan, MD, FAASLD
  Grants: AstraZeneca, Bayer, Gilead, Glycotest; Researcher: Exact Sciences

OFF‐LABEL/INVESTIGATIONAL USE

Presenters are required to disclose at the start of their session if their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

CONTENT DISCLAIMER

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Accreditation

In support of improving patient care, Thomas Jefferson University is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Physicians: This educational activity is designated for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Nurses will be awarded 6.67 nursing contact hours.

Pharmacists: This knowledge-based continuing education activity is designated for 6.67 contact hours of continuing education credit.
UAN #JA4008236-0000-22-004-L01-P

Credits will be uploaded to CPE Monitor within 60 days following the completion of this activity.

This statement contains information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.
 

Other Professionals: This educational activity is designated for 6.75 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Other Credit

Nursing Pharmacology Credit: This educational activity offers 2.0 Nursing Pharmacology credits. Qualifying sessions:

  • NASH: Update on Diagnostic Tools and Novel Therapeutics
  • Treatment Advances in Hepatitis B
  • Autoimmune Hepatitis: Diagnosis and Management
  • A Clinician’s Approach to the Porphyrias

PA Patient Safety and Risk Credit: This educational activity offers 3.25 PA Patient Safety and Risk credit. Qualifying sessions:

  • HCC: A multi-disciplinary team approach to care
  • Sarcopenia and Frailty in Cirrhosis
  • Pre-op Risk Assessment in Patients with Cirrhosis
  • Paradigm Shift in Utilization of Hepatitis C Organs for Transplantation
  • Living Donor Liver Transplantation
  • Advancements in Liver Preservation Technology

Available Credit

  • 6.67 ACPE
  • 6.75 AMA PRA Category 1 Credit
  • 6.75 Attendance
  • 6.67 CNE
  • 2.00 CNE Pharmacotherapy
  • 3.25 Patient Safety

Exhibiting Opportunities

For more information, please contact Ariel Levine.

Price

Cost:
$125.00
Please login or register to take this course.

Registration Fees

Practicing Physician$125
Nurse/Other Health Professionals$90
Jefferson Digestive Disease Network and Jefferson Health Physicians, Nurse and Other Health Professionals$0
All Residents and Fellows $0

 


REGISTRATION INFORMATION

To register online, you must have a CPD @ JeffLearn account.

  1. Login or create an account. - Note: This website will not work on Internet Explorer 8. 
  2. Final price will be reflected on check out. You must be logged in to see the "Add to Cart" function.  
  3. Check out and pay with American Express, Visa or Mastercard. 

REFUNDS

No refunds will be given after Saturday, March 26, 2022. See full refund policy

Requests for refunds must be submitted in writing and received by OCPD before Saturday, March 26, 2022. Registrants who fail to attend the conference are responsible for the entire registration fee. All refunds will be processed after the conference concludes.

Should any emergency arise, of any nature, prior to the opening conference date that would prevent its schedule opening (destruction or damage to the facility by fire, flood, storms, acts of God, etc., or declaration of any emergency by the state of Pennsylvania or the United States Government), Jefferson reserves the right to cancel or postpone the conference. In the event of cancellation or postponement, Jefferson will refund registration fees, but is not responsible for related costs or expenses to registrants, including cancellation fees assessed by hotels, airlines or travel agencies.

RECORDING AND PHOTOGRAPHY STRICTLY PROHIBITED

Unauthorized recording or photography at a Jefferson-sponsored event is strictly prohibited. Individuals found violating this policy will be removed from the online activity or asked to leave from the live activity. No credits or refund will be issued.

JEFFERSON RELEASE POLICY

Jefferson may record/livestream/photograph this activity. These images/recordings, along with your name, may be used in Jefferson publications or on the Jefferson website. If you verbally submit any questions for Q&A sessions, you are agreeing to be recorded and to have that recording available in enduring materials. Once photographed, filmed, recorded, or videotaped, you waive any right of inspection or approval to which such images/recordings may be put and Jefferson has the right to use, publish, reproduce, modify, adapt and distribute at any time in any manner or medium.

You understand that it is your right to withhold consent to this Jefferson policy or to withdraw your previous consent at any time. You further understand that, without your consent, it is not possible to process your course registration request.

JEFFERSON HIPAA POLICY

You understand that, as an attendee of this conference hosted by Thomas Jefferson University, Jefferson University Physicians and Thomas Jefferson University Hospitals, Inc. (collectively “Jefferson”), you may gain access to certain proprietary information (“Confidential Information”), including Protected Health Information (“PHI”).

You agree to maintain the confidentiality of all Confidential Information, including PHI, obtained from any source. You agree that you will take all necessary steps to protect such Confidential Information and shall not directly or indirectly disclose or use it in any manner or for any reason, other than as necessary to complete the activity.

In furtherance of the above, you agree not to take photographs, record in any manner or otherwise reproduce any such Confidential Information. You understand that any unauthorized use or disclosure of Confidential Information by the undersigned may result in possible legal action against you by Jefferson whose confidentiality is breached.